CVS Health posted other positive signs of growth, such as improved retail pharmacy market share. Read why CVS stock is a Buy.

CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions ...

CVS Health reported mixed third-quarter results as higher medical costs squeezed its bottom line. The company expects elevated medical costs to continue to pressure its performance this year, "and as ...

CVS Health on Wednesday reported first-quarter revenue and adjusted earnings that missed expectations. The company also lowered its full-year profit outlook, citing higher medical costs that are ...

CVS Health does a 180. On May 28, CVS Caremark, the pharmacy benefits manager (PBM) under CVS Health's umbrella, announced it ...

CVS Health said on Wednesday that high demand for medical care among older adults hit second-quarter results, a trend that continued into July, causing it to slash its 2024 earnings forecast. CVS took ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

The healthcare giant's stock is up after it posted another solid quarter, which showed a big improvement in its bottom line.

CVS Health (NYSE: CVS) saw its net income expand by $4.2 billion or 101% y-o-y to $8.3 billion in 2023. This can primarily be attributed to the opioid litigation charges included in the 2022 results.